Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis

医学 无容量 肺结核 荟萃分析 入射(几何) 内科学 人口 封锁 数据库 免疫疗法 肿瘤科 癌症 病理 光学 物理 计算机科学 受体 环境卫生
作者
Kewei Liu,Dongpo Wang,Cong Yao,Min Qiao,Qing Li,Weina Ren,Shanshan Li,Mengqiu Gao,Yu Pang
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:13 被引量:18
标识
DOI:10.3389/fimmu.2022.727220
摘要

Objectives In this study, we conducted a systematic review to determine tuberculosis (TB) incidence due to immunotherapy with programmed cell death protein-1 (PD-1)/PD ligand (PD-L1) blockade in cancer patients. Methods We searched PubMed, Cochrance Library, Excerpt Medica Database (Embase), ClinicalTrials.gov, Chinese BioMedical Literature Database (CBM), China National Knowledge Infrastructure Database (CNKI), Wanfang and China Science and Technology Journal Database to identify studies between January 1, 2000 and April 30, 2021, on the reports of TB cases in patients treated with PD-1/PD-L1 blockade. Methodological quality of eligible studies was assessed, and random-effect model meta-analysis was performed to generate the pooled incidence estimate of TB cases in patients undergoing PD-1/PD-L1 therapy. Results We initially identified 745 records, of which 27 studies ultimately met the inclusion criteria and were included in our meta-analysis. A total of 35 TB cases occurred among patients treated with PD-1/PD-L1 blockade. Nivolumab (51.4%) was the most frequently used PD-1/PD-L1 blockade for cancer treatment. In addition, pulmonary TB was the most common form of tuberculosis seen in 77.1% cases. Clinical outcomes were recorded in 18 patients, of whom 77.8% were cured or achieved remission, and 22.2% were died of TB. Pooled analysis determined that the TB rate in this population was 2,000 cases per 100,000 persons, and the estimated rate for TB associated with PD-1/PD-L1 blockade was 35 times higher than that in the general population. Conclusion To conclude, our results demonstrate that the clinical use of PD-1/PD-L1 inhibitors significantly increases risk of TB reactivation. An extremely high mortality rate due to TB disease is noted in the patients with PD-1/PD-L1 blockade.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
1秒前
暴躁小龙发布了新的文献求助10
2秒前
张润泽完成签到 ,获得积分10
2秒前
3秒前
文档发布了新的文献求助10
3秒前
4秒前
6秒前
7秒前
7秒前
8秒前
9秒前
9秒前
烟花应助zwk采纳,获得10
11秒前
蔡芝艳关注了科研通微信公众号
11秒前
YI完成签到,获得积分10
14秒前
14秒前
大个应助科研通管家采纳,获得10
15秒前
15秒前
充电宝应助科研通管家采纳,获得10
16秒前
SYLH应助科研通管家采纳,获得20
16秒前
Ava应助科研通管家采纳,获得10
16秒前
丘比特应助科研通管家采纳,获得10
16秒前
情怀应助科研通管家采纳,获得10
16秒前
Hello应助科研通管家采纳,获得10
16秒前
Owen应助科研通管家采纳,获得10
16秒前
16秒前
su发布了新的文献求助10
18秒前
钟垠州完成签到 ,获得积分10
18秒前
18秒前
活力的妙之完成签到 ,获得积分10
18秒前
丘比特应助只想困瞌睡采纳,获得10
18秒前
小宋发布了新的文献求助10
19秒前
笃定发布了新的文献求助30
21秒前
淡墨完成签到,获得积分10
22秒前
今后应助清漪采纳,获得10
22秒前
zwk发布了新的文献求助10
23秒前
26秒前
鹿君浩发布了新的文献求助10
27秒前
27秒前
小宋完成签到,获得积分10
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158